Despite initially confirming that the Competition and Markets Authority’s (CMA) decision correctly found “flagrantly anti-competitive” cartel behaviour by Auden/Actavis UK and AMCo/Advanz, the Competition Appeal Tribunal (CAT) has today allowed their appeals on what the CMA considers a fundamentally misconceived procedural point.The CAT has allowed the appeals because it considers that the CMA did not fully put its case to former CEO of Advanz John Beighton in cross-examination at trial.The CMA fundamentally disagrees with the CAT’s reasoning and decision to allow the appeals. The CAT’s reasoning overlooks critical evidence that formed the basis for the CMA’s decision and was put to Mr Beighton over two days of cross-examination.The CMA will be seeking leave to appeal the CAT’s decision to ensure the effective enforcement of competition law.Sarah Cardell, Chief Executive Officer of the CMA, said:The CMA imposed significant penalties on these firms after finding they engaged in a market sharing agreement that denied the NHS the potential savings from competition for this essential medicine.We believe the Competition Appeal Tribunal’s decision to allow the appeals is fundamentally misconceived. The impact of this judgment is highly concerning. We will be appealing and remain determined to see this case through. &nbsp;The CAT has today published 2 judgments relating to the CMA’s finding that Auden/Actavis UK paid AMCo/Advanz to stay off the market with its own 10mg hydrocortisone tablets.The first ‘Hydro 2’ judgment was handed down on 29 September 2023. The Hydro 2 judgment upheld the decision’s findings and found that: “All of the grounds of appeal fail. The 10mg Agreement … is a by object infringement of the Chapter I prohibition. The object was flagrantly anti-competitive and the anti-competitive effects significant, in that an abused monopoly position was maintained and supported.”The CAT reached these findings “conscious that we must be satisfied to a very high standard”’ and exercising “an extraordinarily high degree of care in finding the facts”.However, the Hydro 2 judgment expressed concern that the CMA had not fully put its case to Advanz’s witness, former CEO John Beighton, in cross-examination. The judgment remained under embargo pending a further hearing on this point, which took place in October 2023.The CAT’s second judgment in relation to the 10mg agreement (‘Hydro 3’) was handed down today. The judgment finds that the CMA did not fully put its case to Mr Beighton in cross-examination and that for this reason the “provisional” findings in Hydro 2 are “unsafe” and the appeals must be allowed.The Hydro 3 judgment states that without this “due process question” the CAT would be “completely comfortable with the terms and outcome” of the Hydro 2 judgment. It states that if the CMA successfully appeals the due process question, the findings in the Hydro 2 judgment would stand.

CMA Challenges Hydrocortisone Ruling

The CMA imposed penalties on Auden/Actavis UK and AMCo/Advanz for engaging in a market sharing agreement that harmed competition in the hydrocortisone market. The CAT allowed the appeals due to concerns about the CMA's cross-examination of a key witness, former CEO John Beighton. The CMA disagrees with the CAT's decision and will seek to appeal to ensure effective enforcement of competition law. The CAT's judgments, known as 'Hydro 2' and 'Hydro 3', addressed the anti-competitive behavior and procedural issues in the case.

CMA Challenges Hydrocortisone Ruling

The Competition and Markets Authority (CMA) is appealing a decision by the Competition Appeal Tribunal (CAT) that allowed appeals by Auden/Actavis UK and AMCo/Advanz in a case involving anti-competitive cartel behavior in the hydrocortisone market.